CTY
Income statement / Annual
Last year (2019), City Therapeutics Inc.'s total revenue was $8.16 B,
a decrease of 3.96% from the previous year.
In 2019, City Therapeutics Inc.'s net income was $1.83 B.
See City Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
FY-2010
|
| Period Ended |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
12/31/2010 |
| Operating Revenue |
$8.16 B |
$8.49 B |
$8.55 B |
$8.91 B |
$8.96 B |
$8.84 B |
$8.75 B |
$8.85 B |
$6.64 B |
$9.27 B |
| Cost of Revenue |
$2.44 B
|
$2.77 B
|
$2.88 B
|
$2.93 B
|
$2.87 B
|
$2.88 B
|
$2.79 B
|
$2.87 B
|
$1.83 B
|
$1.66 B
|
| Gross Profit |
$5.72 B
|
$5.73 B
|
$5.67 B
|
$5.98 B
|
$6.09 B
|
$5.96 B
|
$5.96 B
|
$5.98 B
|
$4.80 B
|
$7.62 B
|
| Gross Profit Ratio |
0.7
|
0.67
|
0.66
|
0.67
|
0.68
|
0.67
|
0.68
|
0.68
|
0.72
|
0.82
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$659.00 M
|
$799.00 M
|
$925.00 M
|
$1.02 B
|
$1.02 B
|
$1.09 B
|
$1.06 B
|
$1.17 B
|
$1.50 B
|
$152.00 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.46 B
|
| Selling, General & Administrative Expenses |
$659.00 M
|
$799.00 M
|
$925.00 M
|
$1.02 B
|
$1.02 B
|
$1.09 B
|
$1.06 B
|
$1.17 B
|
$1.50 B
|
$1.61 B
|
| Other Expenses |
$0.00
|
$5.03 B
|
$5.31 B
|
$5.57 B
|
$5.69 B
|
$5.64 B
|
$5.61 B
|
$5.78 B
|
$3.94 B
|
$5.18 B
|
| Operating Expenses |
$659.00 M
|
$5.83 B
|
$6.24 B
|
$6.59 B
|
$6.70 B
|
$6.73 B
|
$6.68 B
|
$6.94 B
|
$5.44 B
|
$6.79 B
|
| Cost And Expenses |
$5.27 B
|
$8.60 B
|
$9.12 B
|
$9.52 B
|
$9.58 B
|
$9.61 B
|
$9.47 B
|
$9.81 B
|
$7.27 B
|
$8.44 B
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$448.00 M
|
$465.00 M
|
$478.00 M
|
$473.00 M
|
$464.00 M
|
$450.00 M
|
$443.00 M
|
$0.00
|
-$615.00 M
|
| Depreciation & Amortization |
$1.36 B
|
$1.44 B
|
$1.58 B
|
$1.68 B
|
$1.84 B
|
$1.97 B
|
$2.08 B
|
$2.23 B
|
$1.87 B
|
$1.87 B
|
| EBITDA |
$3.83 B |
$4.04 B |
$3.84 B |
$3.92 B |
$4.05 B |
$4.04 B |
$4.09 B |
$4.06 B |
$2.76 B |
$3.13 B |
| EBITDA Ratio |
0.47
|
0.48
|
0.45
|
0.44
|
0.45
|
0.46
|
0.47
|
0.46
|
0.42
|
0.34
|
| Operating Income Ratio |
0.35
|
0.31
|
0.27
|
0.26
|
0.25
|
0.24
|
0.24
|
0.22
|
0.18
|
0.27
|
| Total Other Income/Expenses Net |
-$416.00 M
|
-$501.00 M
|
-$522.00 M
|
-$559.00 M
|
-$527.00 M
|
-$503.00 M
|
-$512.00 M
|
-$514.00 M
|
-$307.00 M
|
-$610.00 M
|
| Income Before Tax |
$2.47 B
|
$2.16 B
|
$1.79 B
|
$1.76 B
|
$1.73 B
|
$1.61 B
|
$1.57 B
|
$1.39 B
|
$892.00 M
|
$1.87 B
|
| Income Before Tax Ratio |
0.3
|
0.25
|
0.21
|
0.2
|
0.19
|
0.18
|
0.18
|
0.16
|
0.13
|
0.2
|
| Income Tax Expense |
$641.00 M
|
$494.00 M
|
$134.00 M
|
$678.00 M
|
$659.00 M
|
$639.00 M
|
$602.00 M
|
$542.00 M
|
$349.00 M
|
$791.00 M
|
| Net Income |
$1.83 B
|
$1.67 B
|
$1.66 B
|
$1.09 B
|
$1.07 B
|
$970.00 M
|
$964.00 M
|
$849.00 M
|
$543.00 M
|
$1.08 B
|
| Net Income Ratio |
0.22
|
0.2
|
0.19
|
0.12
|
0.12
|
0.11
|
0.11
|
0.1
|
0.08
|
0.12
|
| EPS |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS Diluted |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Weighted Average Shares Out |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
